MEDA Pharmaceuticals Switzerland GmbH - search results

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

solcoseryl 42,5mg/ml solution for i/m and i/v injection

legacy pharmaceuticals switzerland gmbh - hemodialysate from calves blood protein-free - solution for i/m and i/v injection - 42,5mg/ml

solcoseryl 42,5mg/ml solution for i/m and i/v injection

legacy pharmaceuticals switzerland gmbh - hemodialysate from calves blood protein-free - solution for i/m and i/v injection - 42,5mg/ml

solcoseryl 4,15mg/g gel

legacy pharmaceuticals switzerland gmbh - hemodialysate from calves blood protein-free - gel - 4,15mg/g

solcoseryl 2,07mg/g ointment

legacy pharmaceuticals switzerland gmbh - hemodialysate from calves blood protein-free - ointment - 2,07mg/g

disflatyl 40mg/ml drops oral

legacy pharmaceuticals switzerland gmbh - simethicone - drops oral - 40mg/ml

solcovagin solution for topical use

legacy pharmaceuticals switzerland gmbh - nitric acid 70%, glacial acetic acid, oxalic acid dihydrate, zinc nitrate hexahydrate - solution for topical use - 537mg/ml+ 20,4mg/ml+ 58,6mg/ml+ 6mg/ml

solcoseryl ointment

legacy pharmaceuticals switzerland gmbh - protein-free hemodialysate from calves blood - ointment - 2,07mg/g

solcoseryl gel

legacy pharmaceuticals switzerland gmbh - protein-free hemodialysate from calves blood - gel - 4,15mg/g

disflatyl drops oral

legacy pharmaceuticals switzerland gmbh - simeticone - drops oral - 40mg/ml

European Union - English - EMA (European Medicines Agency)

capecitabine medac

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - colorectal neoplasms - antineoplastic agents - capecitabine medac is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine medac is indicated for the treatment of metastatic colorectal cancer.capecitabine medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.